ESTEVE Acquires Caprelsa® to Extend Cancer Treatment Portfolio
Deal News | Jun 30, 2025 | PR Newswire Cision ESTEVE
ESTEVE, a global pharmaceutical company headquartered in Barcelona, has strengthened its position in the oncology market by acquiring the rights to the drug Caprelsa® (vandetanib) from Sanofi. Caprelsa® is a protein tyrosine kinase inhibitor specifically used to treat aggressive and symptomatic medullary thyroid cancer in both adults and children over the age of five. This acquisition supports ESTEVE's strategy of focusing on highly specialized treatments for unmet medical needs. The company views this move as a continuation of its international growth journey, having recently added new drugs to its portfolio through acquisitions in the field of rare and ultra-rare diseases within endocrinology and onco-endocrinology. Jacob Tolstrup, ESTEVE’s Commercial Director, emphasized the company's commitment to improving patient health outcomes worldwide through specialized therapies. Esteve’s acquisition is pending customary regulatory approvals.
Sectors
- Pharmaceuticals
- Biotechnology
- Oncology
Geography
- Spain – ESTEVE, the company acquiring Caprelsa®, is based in Barcelona, Spain.
- France – Sanofi, the company selling the rights to Caprelsa®, is headquartered in France.
- Global – The agreement includes the distribution of Caprelsa® in more than 50 countries, indicating a global impact.
Industry
- Pharmaceuticals – The article discusses ESTEVE's acquisition of a thyroid cancer drug, aligning with the pharmaceutical industry which focuses on creating and acquiring medicinal drugs.
- Biotechnology – The acquisition of a protein tyrosine kinase inhibitor drug from Sanofi aligns with the biotechnology sector, which involves the use of biological processes in drug development.
- Oncology – Since the primary focus of the article is on a cancer drug used for treating thyroid cancer, it falls under the oncology sector which deals with cancer treatment.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ESTEVE | Buyer | Company | An international pharmaceutical company based in Barcelona, focused on treatments for unmet medical needs. |
| Sanofi | Seller | Company | A global healthcare leader headquartered in France, providing a variety of therapeutic solutions. |
| José María Giménez-Arnau | Chief Scientific and Medical Officer | Person | Director at ESTEVE who commented on the partnership in aiding patients with thyroid carcinoma. |
| Jacob Tolstrup | Commercial Director | Person | Director Commercial at ESTEVE emphasizing the company's strategic growth in specialized therapies. |